Safety of MT-401-OTS in Patients With Relapsed AML or MDS

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 16, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions
Acute Myeloid Leukemia, in RelapseMDS
Interventions
DRUG

MT-401-OTS

MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.

Trial Locations (3)

33612

RECRUITING

Moffitt Cancer Center, Tampa

66160

RECRUITING

KU Cancer Center, Kansas City

91006

RECRUITING

City of Hope Center (City of Hope National Medical Center, City of Hope Medical Center), Duarte

Sponsors
All Listed Sponsors
collaborator

University of Kansas Medical Center

OTHER

collaborator

H. Lee Moffitt Cancer Center and Research Institute

OTHER

collaborator

City of Hope National Medical Center

OTHER

lead

Marker Therapeutics, Inc.

INDUSTRY